由于心力衰竭而住院治疗的结果中的性别差异
Sandeep Appunni1, Yanjia Zhang2, Atulya A Khosla3
1Government Medical College, Kozhikode, Kerala, India.
Scientific reports
|November 7, 2024
概括
这项研究发现,心力衰竭 (HF) 住院患者的性别差异显著. 与男性相比,女性的死亡率较低,但住院时间较长,离家出院率更高.
科学领域:
- 心脏病学和心血管疾病.
- 医疗保健服务研究 医疗服务研究
- 医学中的性别和性别.
背景情况:
- 心力衰竭 (HF) 是住院的主要原因,已知基于性别的差异.
- 了解这些差异对于优化患者护理和结果至关重要.
- 之前的研究表明,男女之间HF呈现和管理的潜在差异.
研究的目的:
- 调查成人心力衰竭住院患者临床特征和住院结果的性别差异.
- 为了比较关键结果,包括死亡率,停留时间和男性和女性HF患者之间的资源利用.
主要方法:
- 使用了2016-2019年国家住院样本 (NIS) 数据.
- 包括成人心力衰竭住院情况 (年龄≥41岁),按性别分层.
- 雇员倾向评分与回归分析相匹配,以比较住院结果.
主要成果:
- 分析了4,704,684例初级HF住院病例:52.0%的男性,48.0%的女性.
- 与男性相比,女性的死亡率 (aOR 0.92),机械呼吸 (aOR 0.89),机械循环支持 (aOR 0.54),以及血管压缩剂使用 (aOR 0.71) 显著降低.
- 与男性相比,女性在长时间逗留 (aOR 1.05) 和家庭以外的处置 (aOR 1.32) 的几率明显更高.
结论:
- 在心力衰竭住院结果中存在显著的性别差异.
- 女人经历了更好的生存,但功能恢复较差,释放后资源利用率更高.
- 需要进一步的研究来了解性别对HF流行病学,病变发生和治疗反应的影响.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.5K
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
14.4K
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: β-Blockers
319
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
319
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:22Heart Failure Drugs: Diuretics
345
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
01:12Hazard Ratio
91
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
91